Losartan significantly reduces the aortic root dilation rate in MFS patients with an HI-FBN1 mutation, whereas only a modest insignificant reduction is found in those with a DN-FBN1 mutation, which highlights the importance of genetics in MFS. This evidence concerns the gene FBN1 and Marfan syndrome.